Posttraumatic stress disorder (PTSD) does not discriminate and can affect anyone who experiences a catastrophic event or events over their lifetime. It is estimated that more than 80% of adults in the United States experience traumatic events that would qualify for a PTSD diagnosis and at any given time 24.4 million Americans have PTSD. The annual cost to society of anxiety disorders is estimated to exceed well over $42.3 billion due to psychiatric and non-psychiatric medical treatment costs, indirect workplace costs, mortality costs, and prescription drug costs. Anxiety and stress-related disorders are without question one of the largest public health concerns to date. In this study a systematic review was conducted to build a case for efficacy of hypothesized somatic pharmacologic PTSD interventions. Hypothesized somatic pharmacologic PTSD interventions (ketamine, oxytocin, cannabinoids, opioids, omega-3, modafinil, and albuterol) were investigated and results were gathered to support efficacy for further research or use in randomized controlled trials. All of the study designs, models, and reviews utilized in this systematic review generated positive results by showing a reduction in posttraumatic stress symptoms or preventing PTSD development. Findings suggest that there is efficacy for further research and development into hypothesized somatic pharmacologic PTSD interventions. Further development of hypothesized somatic pharmacologic PTSD interventions may be the answer to eliminating PTSD or drastically reducing its symptoms.
Keywords: Posttraumatic Stress Disorder, Pharmacologic, Primary Prevention, Pre Trauma, Secondary Prevention, Pre-symptomatic, Somatic
Posttraumatic stress disorder (PTSD) does not discriminate and can affect anyone who experiences a catastrophic eventMay 4, 2019 in Nursing & Health Care Assignment Help